Does Group Health Cooperative (GHC) Cover Wegovy?
The verdict
Conditional on most plans
Group Health Cooperative's Wegovy coverage for weight loss is employer-dependent and not publicly published. GHC is a member-owned cooperative in Wisconsin — a different ownership model from neighboring commercial Wisconsin plans like Network Health (commercial insurer) and Quartz (provider-owned cooperative), but the same core coverage logic applies: weight-loss Wegovy is covered only where the employer group purchased the anti-obesity benefit.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Group Health Cooperative using your member ID.
Key facts
Group Health Cooperative is a member-owned cooperative in Wisconsin — one of three Wisconsin plans in this cluster (alongside Network Health and Quartz) where Wegovy weight-loss coverage is employer-dependent and not publicly published.
GHC plan materials
Wegovy's list price is $1,349/month; Novo Nordisk announced a reduction to approximately $675/month effective January 1, 2027.
Novo Nordisk press release, 2026
The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare beneficiaries Wegovy weight-loss access at $50/month outside Part D — not counting toward the $2,100 OOP cap.
CMS.gov, Medicare GLP-1 Weight Loss Drug Access Program
Medicare vs. commercial coverage
Whether Group Health Cooperative covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by statute — this applies to all GHC Medicare plans. GHC Medicare plans can cover Wegovy for the cardiovascular risk-reduction indication (FDA-approved for adults with established CVD who are overweight or obese) with prior authorization. The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare beneficiaries weight-loss access to Wegovy at $50/month through December 31, 2027 — this operates outside Part D, so the $50 does not count toward the $2,100 OOP cap or TrOOP. Extra Help cannot be applied to Bridge copays. NovoCare savings card is not available to Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
GHC commercial and employer plans cover Wegovy for weight loss only when the employer has purchased the anti-obesity benefit. Where the benefit is included, prior authorization is required: BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea), plus documented lifestyle program participation and weight-loss maintenance for renewal. Where the employer did not opt in, Wegovy for weight loss is excluded — this is a benefit design decision, not a medical-necessity denial, and appeals will not succeed. ACA/individual-market plans generally exclude Wegovy for weight loss. Wisconsin Medicaid GLP-1 obesity coverage is state-dependent; verify on the WI Medicaid PDL. Per-plan drug tier and cost-share are not publicly published; verify via GHC's drug-lookup tool. Commercially insured GHC members whose plan covers Wegovy may use the NovoCare savings card at $25/month (max $100 per 28-day supply; not available to Medicare or Medicaid).
The 4 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price for a 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period through December 31, 2026.
List price with no coverage — before any manufacturer savings card.
With coverage
Plan-specific cost-share where covered — not publicly published at the drug level. Confirm your specific cost-share on GHC's drug-lookup tool or member portal. NovoCare savings card: commercially insured GHC members whose plan covers Wegovy may pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medicaid beneficiaries.
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month fixed copay for eligible Medicare beneficiaries, launching July 1, 2026, through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap, TrOOP, or Extra Help. Provider must attest eligibility at initiation.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. Actual cost-share varies by plan tier, deductible phase, and pharmacy — confirm with your GHC plan and pharmacist before starting treatment.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Ask HR whether your employer included the anti-obesity benefit
Because GHC does not publish drug-level Wegovy detail, confirm with your HR benefits team whether anti-obesity medications are in your employer plan. As a cooperative, GHC's benefit design can vary by employer group. If the benefit is excluded, no PA will succeed — it is a benefit design decision.
- 2
Search GHC's drug-lookup tool for your specific plan
Go to ghcscw.com (or your local GHC affiliate site) and use the formulary or drug-lookup tool with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to confirm tier, PA requirements, and quantity limits for your actual plan.
- 3
Work with your prescriber on prior authorization
If your plan covers Wegovy, your doctor will submit a PA to GHC. Gather documentation: BMI measurement, relevant comorbidities, and evidence of lifestyle program participation. Track weight-loss progress before each renewal to meet the reauthorization threshold.
Options if Group Health Cooperative won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide for T2D)
If you have type 2 diabetes, Ozempic (semaglutide) is broadly covered for T2D with PA across most commercial plans regardless of the anti-obesity benefit. Ozempic is not FDA-approved for weight loss and should not be prescribed for that indication.
NovoCare self-pay program
Novo Nordisk's NovoCare Pharmacy offers Wegovy at approximately $349/month for patients without coverage. An introductory rate of approximately $199/month applies to the 0.25 and 0.5 mg doses through December 31, 2026. List price is announced to drop to approximately $675/month effective January 1, 2027.
Compounded semaglutide
Compounded semaglutide is available without insurance for patients who cannot access covered Wegovy. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
GHC covers Wegovy for weight loss only on employer plans where the anti-obesity benefit was purchased. As a member-owned cooperative, GHC does not publish drug-level Wegovy detail publicly — the only way to confirm coverage is through the drug-lookup tool at ghcscw.com or by calling member services. ACA/individual plans generally exclude weight-loss GLP-1s. If the employer excluded the anti-obesity benefit, no PA will override that decision.
All three are Wisconsin plans with not-publicly-published Wegovy detail gating weight-loss coverage on employer opt-in. The distinctions are structural: GHC is a member-owned cooperative, Network Health is a commercial insurer with a notable Medicare Advantage book, and Quartz is a provider-owned cooperative. For commercial weight-loss seekers, the decision variable is identical across all three — your employer's benefit design. Members of any Wisconsin plan should verify on their specific drug-lookup tool rather than assuming the plans behave identically.
Where the anti-obesity benefit is included in the employer plan, GHC requires PA with BMI 30 or higher (or 27 with a weight-related comorbidity such as hypertension, T2D, dyslipidemia, or sleep apnea), documented lifestyle program participation, and demonstrated weight-loss progress for renewal. Specific GHC PA criteria are not publicly published — confirm current requirements with GHC member services or your prescriber before submitting.
No. Medicare Part D cannot cover Wegovy for weight loss by statute — this is a federal rule applying to all plans including GHC Medicare plans. GHC Medicare plans can cover Wegovy for the cardiovascular risk-reduction indication in members with established CVD. The Medicare GLP-1 Bridge (launching July 1, 2026) provides weight-loss access at $50/month outside Part D for eligible beneficiaries — verify Bridge eligibility criteria with your prescriber.
Group Health Cooperative is member-owned, meaning enrollees have a structural stake in the plan's governance. In practice, Wegovy coverage follows the same employer-benefit-design logic as for-profit Wisconsin plans: the employer must purchase the anti-obesity benefit for weight-loss coverage to apply. Being a cooperative does not result in broader or more automatic anti-obesity drug coverage. The main member benefit of the cooperative model is cost accountability and governance participation — not a categorical advantage in GLP-1 coverage.
Related Articles
Does Quartz Health Solutions Cover Wegovy? 2026 | Curex
Quartz Health Solutions covers Wegovy only where your employer opted into the anti-obesity benefit. Not publicly published — verify on Quartz's formulary.
Read moreDoes Geisinger Health Plan Cover Wegovy? 2026 | Curex
Geisinger Wegovy coverage is employer-dependent and unpublished. PA Medicaid dropped GLP-1 obesity coverage in 2026. How to verify.
Read moreDoes Security Health Plan Cover Wegovy? 2026 | Curex
Security Health Plan (Marshfield Clinic) covers Wegovy only where your employer opted in. Not publicly published — verify on the plan's drug-lookup tool.
Read moreDoes Fallon Community Health Plan Cover Wegovy? | Curex
Fallon covers Wegovy only where your employer opted in. New England is tightening — BCBS-MA ended GLP-1 coverage in 2026. Verify your plan.
Read moreDoes UPMC Health Plan Cover Wegovy? PA Plans 2026 | Curex
UPMC covers Wegovy for weight loss only where employers opted in. PA Medicaid dropped GLP-1 obesity coverage January 2026. Verify on UPMC drug lookup.
Read moreDoes Harvard Pilgrim Health Care Cover Wegovy? 2026 | Curex
Harvard Pilgrim covers Wegovy only where your employer opted in. New England GLP-1 market tightening — BCBS-MA exited 2026. Verify on the drug-lookup tool.
Read moreWhether or not Group Health Cooperative covers Wegovy, there's a path that skips insurance
Group Health Cooperative covers Wegovy for weight loss only where the employer opted in. For patients without that benefit, Curex offers compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) at getcurex.com/cl/glp — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Group Health Cooperative before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.